In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here: FDA approves Vabysmo prefilled syringe for retinal diseases VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates FDA approves Eylea biosimilar FYB203/Ahzantive VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study ANI Pharmaceuticals to acquire Alimera Sciences References: Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah. Healio Interviews Press Release Press Release Press Release Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

Ver todos los episodios